Robert Clarke is stepping down as CEO of DPI developer Pulmatrix and will be succeeded immediately by current Chief Business Officer Ted Raad, the company said. Clarke, who was appointed CEO in 2012, will stay on through August 14, 2019 as an advisor.
Clarke said, “After fifteen years at Pulmatrix growing with the organization from Head of R&D to CSO and ultimately to CEO, I’ve had the opportunity to see every aspect of the company’s business. With the Pulmazole program partnered with Cipla Technologies, and a strong balance sheet for future development, I believe that the business is now heading into a promising phase of its evolution under Ted’s capable leadership. I look forward to the future success of Pulmatrix as the company’s products get to patients in need.”
Pulmatrix Chairman Mark Iwicki commented, “The Pulmatrix Board of Directors appreciates the contributions of Dr. Clarke in leading Pulmatrix through the critical stages of an early-stage development-focused company. Bob was integral in the development of Pulmatrix’s iSPERSE inhaled drug delivery platform and product pipeline. As CEO, Bob also led the company through the transition from a private to public company. We wish the best for Bob. We believe that Ted is well positioned to lead Pulmatrix into a late-stage development and commercial organization. Ted recently led completion of Pulmatrix’s partnership with Cipla Technologies for the development and commercialization of Pulmazole and brings a breadth and depth of executive management, clinical development and commercial experience to the role.”
Raad added, “I personally want to thank Bob for his contributions and bringing me to the company. Pulmatrix has the potential to transform patient care in respiratory disease. In addition to Pulmazole beginning Phase 2, we look forward to advancing PUR1800 towards the clinic. We have a robust pipeline where each product has the potential to positively impact patient lives.”
Read the Pulmatrix press release.
